Such a trial-and-error approach is expensive and costs lives, because several diseases, such as Alzheimer's, are best treated as soon as they are diagnosed.
Callaway argued that the KPMG approach was needed only if it had committed an error in setting up the fund--and that a change in return estimates wasn't an error.